Form 8-K - Current report:
SEC Accession No. 0001104659-13-018165
Filing Date
2013-03-07
Accepted
2013-03-07 08:10:38
Documents
16
Period of Report
2013-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a13-6660_18k.htm 8-K 29175
2 EX-99.1 a13-6660_1ex99d1.htm EX-99.1 137950
3 EX-99.2 a13-6660_1ex99d2.htm EX-99.2 23917
4 GRAPHIC g66601moi001.gif GRAPHIC 180825
5 GRAPHIC g66601moi002.gif GRAPHIC 86836
6 GRAPHIC g66601moi003.gif GRAPHIC 98055
7 GRAPHIC g66601moi004.gif GRAPHIC 40931
8 GRAPHIC g66601moi005.jpg GRAPHIC 89563
9 GRAPHIC g66601moi006.gif GRAPHIC 80926
10 GRAPHIC g66601moi007.gif GRAPHIC 98266
11 GRAPHIC g66601moi008.gif GRAPHIC 50207
12 GRAPHIC g66601moi009.jpg GRAPHIC 62490
13 GRAPHIC g66601moi010.gif GRAPHIC 46047
14 GRAPHIC g66601moi011.gif GRAPHIC 41662
15 GRAPHIC g66601moi012.gif GRAPHIC 178687
16 GRAPHIC g66601mmi001.jpg GRAPHIC 3870
  Complete submission text file 0001104659-13-018165.txt   1652483
Mailing Address 119 FOURTH AVE NEEDHAM MA 02494-2725
Business Address 119 FOURTH AVE NEEDHAM MA 02494 7814330771
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 13671571
SIC: 2835 In Vitro & In Vivo Diagnostic Substances